Dakota Wealth Management Has $9.15 Million Holdings in Amgen Inc. $AMGN

Dakota Wealth Management trimmed its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 25.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 32,414 shares of the medical research company’s stock after selling 11,003 shares during the period. Dakota Wealth Management’s holdings in Amgen were worth $9,147,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Portland Global Advisors LLC raised its position in Amgen by 1.2% in the 3rd quarter. Portland Global Advisors LLC now owns 24,065 shares of the medical research company’s stock worth $6,791,000 after purchasing an additional 287 shares during the last quarter. Cary Street Partners Investment Advisory LLC increased its stake in shares of Amgen by 28.0% in the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 1,885 shares of the medical research company’s stock valued at $532,000 after buying an additional 412 shares during the period. MainStreet Investment Advisors LLC raised its position in shares of Amgen by 11.3% during the third quarter. MainStreet Investment Advisors LLC now owns 1,825 shares of the medical research company’s stock worth $515,000 after acquiring an additional 186 shares during the last quarter. Trajan Wealth LLC lifted its stake in shares of Amgen by 0.9% during the third quarter. Trajan Wealth LLC now owns 16,684 shares of the medical research company’s stock valued at $4,708,000 after acquiring an additional 148 shares during the period. Finally, Clearstead Advisors LLC boosted its holdings in Amgen by 0.4% in the third quarter. Clearstead Advisors LLC now owns 35,799 shares of the medical research company’s stock valued at $10,102,000 after acquiring an additional 129 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Trading Up 1.2%

Shares of NASDAQ AMGN opened at $379.42 on Tuesday. Amgen Inc. has a twelve month low of $261.43 and a twelve month high of $385.12. The stock has a market cap of $204.53 billion, a price-to-earnings ratio of 26.66, a P/E/G ratio of 3.71 and a beta of 0.46. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78. The company’s fifty day moving average is $344.29 and its 200-day moving average is $317.21.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, topping the consensus estimate of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The business had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. During the same quarter last year, the business posted $5.31 EPS. The firm’s revenue was up 8.6% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Equities research analysts predict that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, February 13th will be issued a dividend of $2.52 per share. This is an increase from Amgen’s previous quarterly dividend of $2.38. The ex-dividend date is Friday, February 13th. This represents a $10.08 annualized dividend and a yield of 2.7%. Amgen’s dividend payout ratio is 70.84%.

Wall Street Analyst Weigh In

AMGN has been the subject of several recent research reports. Weiss Ratings reissued a “buy (b)” rating on shares of Amgen in a report on Monday, December 29th. Mizuho boosted their price target on shares of Amgen from $280.00 to $295.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 10th. Daiwa Securities Group raised their price objective on shares of Amgen from $370.00 to $410.00 and gave the company an “outperform” rating in a research note on Tuesday, February 10th. BMO Capital Markets lifted their target price on shares of Amgen from $335.00 to $372.00 and gave the stock an “outperform” rating in a report on Wednesday, December 3rd. Finally, Rothschild & Co Redburn increased their price target on Amgen from $180.00 to $200.00 and gave the company a “sell” rating in a research note on Wednesday, February 18th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, eleven have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $351.76.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.